MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA," the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the trial design for ...
Growing Demand for Thio Chemicals Across Various Industries is Driving the MarketRockville, MD , March 05, 2025 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence ...
THIO, a first-in-class agent, targets telomeres, inducing cancer cell death and activating immune responses in NSCLC. The THIO-101 trial showed a median overall survival of 16.9 months, surpassing ...
Hosted on MSN1mon
MAIA Biotechnology announces updated data from THIO-101 trialMAIA Biotechnology (MAIA) announced updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, THIO, sequenced with Regeneron’s (REGN) immune ...
MAIA Biotechnology (MAIA) announced the trial design for the expansion of its THIO-101 pivotal Phase 2 trial in non-small cell lung cancer ...
MAIA Biotechnology (MAIA) announced plans to initiate a Phase 3 pivotal trial in 2025, named THIO-104, to evaluate the efficacy of THIO ...
SINGAPORE] The first leg of this year’s The Business Times Corporate Golf League is over, and already things are looking ...
Following successful outcomes to date in THIO-101, the expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback